Drug Approval | January 30, 2023
FDA approves Keytruda as adjuvant treatment for non-small cell lung cancer
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
The WHO has urged China to increase adoption of mRNA vaccines, given their high efficacy against variant strains.
Biocon Foundation has pioneered a mHealth-technology-based (mobile health) oral cancer screening program in India
Cell sorting technology supports researchers advancing new therapies
Asthma patients are more likely to have an asthma attack during winter
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
The goal is to bring oncology therapy closer to the communities by integrating all services such as chemotherapy and radiation centers
Subscribe To Our Newsletter & Stay Updated
